SpyGlass Pharma, Inc.

SpyGlass Pharma (SGP) shows zero cyber incidents and zero red-flag 8-K filings in our 90-day monitoring window, suggesting operational stability in the near term. However, low signal in a compressed timeframe doesn't indicate the full risk picture—the company's financing history, equity dilution trajectory, and structural vulnerabilities may extend well beyond recent quarters. The full $49 Report extends analysis to 12 months of SEC filings, applies dilution scoring, and flags AI-detected risk signals in capital structure and clinical-stage cash burn dynamics that a snapshot cannot capture. The full $49 Report adds dilution risk scoring, 12-month 8-K context, financing history analysis, and AI risk signals across clinical-stage operations.